# Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults

> **NCT05978908** · PHASE1 · COMPLETED · sponsor: **Neurodegenerative Disease Research Inc** · enrollment: 24 (actual)

## Conditions studied

- Safety Issues
- Tolerance

## Interventions

- **DRUG:** FC-12738
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT05978908
- **Lead sponsor:** Neurodegenerative Disease Research Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-20
- **Primary completion:** 2024-06-03
- **Final completion:** 2024-06-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05978908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05978908, "Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05978908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*